MyFinsight
Home
Blog
About
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Legal settlement liability
Change in deferred r&d services ...
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Net loss
Accounts receivable
Insurance recovery asset
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
-
-
5,092
30,485
Total selling, general and administrative
-
-
8,117
27,103
Total research and development
-
-
2,520
6,335
Loss on disposal of assets
-
-
-246
-
Cost of product revenue
-
-
2,192
-
Cost of revenue
-
-
-
2,040
Cost of license and collaboration revenue
-
-
1,249
-
Other segment items
-
-
882
4,819
Net loss
-13,153
-9,682
-8,074
-9,812
Stock-based compensation
1,213
897
686
718
Depreciation expense
15
17
14
23
Non-cash interest expense
0
0
400
716
Impairment of right-of-use asset
-
-
0
-
Loss on disposal of fixed assets
0
-
0
-68
Loss on termination of financing lease
0
-10
2
1
Amortization of operating lease right-of-use asset
79
77
76
74
Amortization of finance lease right-of-use asset
113
100
100
87
Change in obligation for r&d funding liability
-
-
754
-
Change in deferred r&d services and r&d funding liability
2,904
1,332
-
-
Non-cash accretion of r&d funding liability
-
-
-
375
Loss on extinguishment of debt
-
-
-1,533
-
Non-cash r&d expense related to torii warrant vesting
192
106
51
-
Change in fair value of derivative liability
0
0
1,762
34
Prepaid expenses and other assets
251
-433
-1,012
2,094
Collaboration receivable, billed and unbilled
62
-48
-145
-7,896
Insurance recovery asset
2,302
-
-
-
Inventory
738
-103
-
-218
Accounts payable
-590
121
487
-736
Legal settlement liability
4,000
-
-
-
Deferred revenue
304
249
-782
1,564
Accounts receivable
3,215
2,464
-1,787
-2,146
Accrued expenses and other current liabilities
2,297
-586
-400
-501
Operating lease liability
-84
-83
-82
-79
Net cash used in operating activities
-9,278
-9,163
-4,591
9,685
Purchases of property and equipment
-
-
0
0
Sale of fixed assets
-
-
0
-
Net cash used in investing activities
0
0
0
0
Proceeds from exercise of stock options
-
-
0
0
Debt amendment costs
-
-
110
0
Cash paid to settle debt
-
-
35,030
-
Proceeds from issuance of debt, net of issuance costs
-
-
0
-
Repayment of debt
0
0
870
3,890
Proceeds from issuance of common stock, pre-funded warrants and warrants
-
-
50,067
-
Repayment of finance lease
126
111
106
94
Payment of equity issuance costs
0
9
310
0
Net cash used in financing activities
-126
-120
13,641
-3,984
Net decrease in cash and restricted cash
-9,404
-9,283
9,050
5,701
Cash and restricted cash at the beginning of the period
20,864
30,147
21,097
46,329
Cash and restricted cash at the end of the period
11,460
-
-
-
Cash
11,198
-
-
-
Restricted cash
262
-
-
-
Total cash and restricted cash
11,460
20,864
30,147
21,097
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in cash
and restricted cash
-$9,404K
(69.60%↑ Y/Y)
Legal settlement
liability
$4,000K
Change in deferred r&d
services and r&d funding...
$2,904K
Accrued expenses and
other current...
$2,297K
(660.24%↑ Y/Y)
Stock-based compensation
$1,213K
(-36.62%↓ Y/Y)
Deferred revenue
$304K
(-36.80%↓ Y/Y)
Non-cash r&d expense
related to torii warrant...
$192K
Amortization of finance lease
right-of-use asset
$113K
(-31.52%↓ Y/Y)
Amortization of operating
lease right-of-use...
$79K
(-45.89%↓ Y/Y)
Depreciation expense
$15K
(-84.38%↓ Y/Y)
Net cash used in
operating activities
-$9,278K
(59.17%↑ Y/Y)
Net cash used in
financing activities
-$126K
(98.47%↑ Y/Y)
Canceled cashflow
$11,117K
Net loss
-$13,153K
(-37.90%↓ Y/Y)
Repayment of finance lease
$126K
(-31.15%↓ Y/Y)
Accounts receivable
$3,215K
(-64.84%↓ Y/Y)
Insurance recovery asset
$2,302K
Inventory
$738K
(1150.85%↑ Y/Y)
Accounts payable
-$590K
(-238.82%↓ Y/Y)
Prepaid expenses and
other assets
$251K
(130.68%↑ Y/Y)
Operating lease liability
-$84K
(45.45%↑ Y/Y)
Collaboration receivable,
billed and unbilled
$62K
(-99.24%↓ Y/Y)
Buy us a coffee